SEARCH:   Advanced

Blood, Vol. 113, Issue 26, 6629-6637, June 25, 2009 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef IL-7 adjuvant treatment enhances long-term tumor antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector Blood Colombetti et al. 113: 6629 Supplemental materials for: Colombetti et al Files in this Data Supplement: Figure S1. Similar downregulation of CD5 on antigen-specific CD8+ T cells upon rec.lv/M-A26–35 and adj/M-A26–35 immunizations (JPG, 61.9 KB) - Mice were immunized with rec.lv/M-A26–35 and adj/M-A26–35. At the peak of the response (day 20 after rec.lv/M-A26–35 and day 7 after adj/M-A26–35 immunization) the expression of CD5 in Tet+ and Tet− CD8+ T-cell populations was measured. (A) Representative histogram plots of CD5 expression in Tet+ and Tet− CD8+ T cells. (B) Fold decrease of CD5 expression (MFI) in Tet+ CD8+ T cells compared to Tet− CD8+ T cells after immunization. Results represent the mean +∕− SD of 7–9 mice per group. Figure S2. Long-term kinetics of rec. lv-induced Melan-A–specific CD8+ T-cell responses in the absence or in the presence of IL-7 adjuvant therapy (JPG, 16.9 KB) - A2/Kb mice immunized with rec. lv/M-A26–35 were either left untreated (thick line) or treated with rIL-7 (5µg/day) (dashed line) during the effector phase of the immune response (day 10–23). At the indicated time points after immunization, the frequency of Melan-A–specific CD8+ T cells (Tet+) was measured ex vivo by staining peripheral blood cells with Melan-A26–35/A2Kb tetramers. Each symbol represents the average of at least 7 mice. Results represent the mean +∕− SD of 7 mice per group. *, p< 0.05. Figure S3. IL-7 adjuvant treatment increases gp100-specific memory CD8+ T-cell responses upon immunization with rec. lv (JPG, 36.4 KB) - C57BL/6 mice were immunized either with rec. lv encoding gp10025–33 (rec. lv/gp10025–33) or with peptides gp10025–33 in adjuvants (adj/gp10025–33). (A) At the peak of the response, PBMC were stained with gp10025–33/H-2Db tetramers. Left panels: dot plots represent the expression of CD62L and CD127 on Tet+ CD8+ T cells for one representative experiment. Right panels: mice were either left untreated (filled circles) or treated with rIL-7 (5µg/day) (empty circles) during the effector phase of the immune response (day 10–20 and day 6–14 for rec. lv/gp10025–33 and adj/gp10025–33 immunizations, respectively). The number of Tet+ CD8+ T cells per ml of blood at the peak of the response is shown. (B) The number of Tet+ CD8+ T cells per ml of blood at the memory phase is shown. 5 mice per group are represented. Horizontal bars indicate mean values. *, p< 0.05. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020